Bifogade filer
File
Kurs
+8,47%
Kalender
| Tid* | ||
| 2025-05-12 | N/A | X-dag ordinarie utdelning ATANA 0.00 SEK |
| 2025-05-09 | N/A | Årsstämma |
| 2025-05-09 | 21:30 | Kvartalsrapport 2025-Q1 |
| 2025-02-21 | 21:30 | Bokslutskommuniké 2024 |
| 2024-11-01 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-31 | - | Extra Bolagsstämma 2025 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-03 | - | Årsstämma |
| 2024-05-03 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-10-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-18 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-08 | - | X-dag ordinarie utdelning ATANA 0.00 SEK |
| 2023-05-05 | - | Årsstämma |
| 2023-05-05 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2022-12-07 | - | Extra Bolagsstämma 2022 |
| 2022-11-25 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-09 | - | X-dag ordinarie utdelning ATANA 0.00 SEK |
| 2022-05-06 | - | Årsstämma |
| 2022-05-06 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-11-26 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-17 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-10 | - | X-dag ordinarie utdelning ATANA 0.00 SEK |
| 2021-05-07 | - | Årsstämma |
| 2021-05-07 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-27 | - | Kvartalsrapport 2020-Q3 |
| 2020-11-09 | - | Extra Bolagsstämma 2020 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-11 | - | X-dag ordinarie utdelning ATANA 0.00 SEK |
| 2020-05-08 | - | Årsstämma |
| 2020-05-08 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-24 | - | Bokslutskommuniké 2019 |
| 2019-11-29 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-09 | - | Extra Bolagsstämma 2019 |
| 2019-08-07 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-08 | - | X-dag ordinarie utdelning ATANA 0.00 SEK |
| 2019-05-07 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-05 | - | Årsstämma |
| 2019-02-26 | - | Bokslutskommuniké 2018 |
| 2018-05-08 | - | X-dag ordinarie utdelning ATANA 0.00 SEK |
| 2018-05-07 | - | Årsstämma |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Nordic SME Sweden |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
We are happy to have been part of very important research project studying how a virus can infect human cells. In the paper "Crimean-Congo haemorrhagic fever virus uses LDLR to bind and enter host cells (https://www.nature.com/articles/s41564-024-01672-3)" Vanessa Monteil, Shane Wright, and co-workers at Karolinska Institutet shows how CCHF virus is able to enter cells using Low Density Lipoprotein Receptor (LDLR) and glycoproteins to obtain high affinity interactions between the virus and cells. Attana technology was used to determine affinity and kinetics of the interactions and to elucidate the role of different glycoproteins.
CCHF virus is primarily transmitted to humans via tick bites, but humans can also infect each other. Usually, infected individuals develop fever and pain, but in the worst case it can lead to organ failure and death. The current publication is part of a larger project (https://news.ki.se/promising-drug-candidates-for-crimean-congo-haemorrhagic-fever-identified) to develop drugs against the virus, led by Docent Ali Mirazimi.
Teodor Aastrup, CEO
ir@attana.com (teodor.aastrup@attana.com)
+46 708 86 23 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.